Cancer Costs Call for Clever Use of Capital, States GBI Research
06 Aug 2012 • by Natalie Aster
Healthcare systems across the globe need to find new ways to fund cancer treatments, according to a new report by healthcare experts GBI Research.
The report "Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities" by GBI Research, shows financial issues arising from oncology therapy costs in Europe and the US. This implies that better insurance guidelines and a bigger cash injection is needed to support the gigantic patient population.
As oncology therapy costs increase, healthcare systems across the globe will need to adapt and find new ways to fund cancer treatments. Better insurance guidelines and a bigger cash injection will be required to support the increasing patient population. Surgery was once considered to be the most effective cancer therapy but the approval of new molecularly targeted anti-cancer drugs represents a new and exciting advancement in clinical oncology. These drugs offer benefits which include improvement in survival, pain reduction, and an overall improvement in quality of life. However, access to treatment is controlled by government policies, which are often influenced by economic limitations so these new anti-cancer drugs unfortunately come with a heavy price tag. Combination therapies are already increasing the cost of drug therapy meaning that some are struggling to afford treatment costs. Therefore the usage of ground-breaking anti-cancer drugs can differ dramatically between different countries.
Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities
Published: July, 2012
Price: US$ 3.500,00
Higher levels of performance are now demanded from oncology treatments in terms of survival and remission, in order for the drug to qualify for reimbursement, as insurance bodies now scrutinize the benefits derived from therapies more rigorously than before. In Italy the Agenzia Italiana del Farmaco (AIFA) - the Italian Medicines Agency - has developed a health technology assessment (HTA) system for anti-cancer drugs, to manage the delivery and funding of novel and expensive drugs. Other advanced economies are also now adopting similar conditional reimbursement agreements, and in light of new upcoming anti-cancer drugs and this trend is set to continue.
More information can be found in the report “Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities” by GBI Research.
To order the report or ask for sample pages contact [email protected]